Antitumor Immunity Induced by Antibody-Based Natural Killer Cell Engager Therapeutics Armed with Not-Alpha IL-2 Variant

Investigators reported the design of tetraspecific molecules engaging natural killer cell-activating receptors NKp46 and CD16a, the β-chain of the interleukin-2 receptor, and a tumor-associated antigen.